REGN vs TEVA
Regeneron Pharmaceuticals, Inc. (REGN) and Teva Pharmaceutical Industries Ltd (TEVA) are both filed with the SEC under Pharmaceutical Preparations. REGN is 1.7× TEVA's size by market cap ($75.9B against $43.8B); TEVA trades at the higher fiscal-year P/E (31.1× against 19.5×); REGN reports the higher net margin (31.4% against 8.2%); REGN grew sales faster over three years (+5.6% against +5.0%); and over the past year TEVA returned +102.0% against REGN's +37.6%.
| REGN | TEVA | |
|---|---|---|
| Last close | $794.19 | $36.44 |
| Market cap | $75.9B | $43.8B |
| P/E (FY) | 19.5× | 31.1× |
| P/S | 5.3× | 2.5× |
| EV/EBITDA | 16.8× | 13.3× |
| Gross margin | — | 51.8% |
| Operating margin | 24.9% | 12.5% |
| Net margin | 31.4% | 8.2% |
| Return on equity | 14.9% | 21.2% |
| Sales growth (3y) | +5.6% | +5.0% |
| EPS growth (3y) | +2.8% | — |
| Dividend yield | 0.5% | — |
| 1-year return | +37.6% | +102.0% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year — FY2025 (ended 2025-12-31) for both. — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| REGN | TEVA | |
|---|---|---|
| Institutional holders (13F) | 1,384 | 649 |
| Insider buyers − sellers (180d) | -1 | -5 |
| Congressional trades disclosed (180d) | 2 | 1 |
| Executive-branch officials on file — trades disclosed (180d) | 7 | 0 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5.
REGN vs TEVA: common questions
- Is REGN bigger than TEVA?
- REGN carries the larger market cap — $75.9B against $43.8B, both struck on 2026-08-27.
- Which trades at a higher P/E, REGN or TEVA?
- TEVA, at a fiscal-year 31.1× against 19.5× for REGN. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have REGN and TEVA performed over the past year?
- TEVA returned +102.0% and REGN +37.6%, measured on the trailing calendar year to the last close.
- How many institutions hold REGN and TEVA?
- 1,384 13F filers report a position in REGN and 649 in TEVA, on the latest quarter in the panel.
- Are REGN and TEVA in the same industry?
- Both are filed with the SEC under Pharmaceutical Preparations, which is the classification this pairing is built on.
REGN overview → · TEVA overview → · REGN institutional ownership → · TEVA institutional ownership → · Congress and REGN → · Congress and TEVA → · Executive branch and REGN →
More in Pharmaceutical Preparations: ABBV vs ABT · ABBV vs ONC · ABBV vs REGN · ABBV vs TEVA
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/regn-vs-teva